Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes. Our team of scientists have developed a novel cell and immune-evasion technologies that, together, reverse diabetes in animal models. We are currently working to advance this therapy to the clinic.
William L. Rust, Ph.D. Chief Executive Officer and Founder
William Rust developed the technology and strategy behind the Seraxis islets and SeraGraft©. He successfully guided the development of Seraxis from start-up through three rounds of financing to position Seraxis as an industry leader in cell replacement therapy for type 1 diabetes.
Carole A. Welsch, Ph.D., MBA, Chief Business Officer
Carole Welsch has over 18 years of experience in the pharmaceutical and biotech industry. She oversees the company’s financing and regulatory strategy. She is also instrumental in the execution of partnerships and the management of Seraxis intellectual property portfolio.
Board of Directors
Arup Roy, PhD
Arup Roy, PhD currently serves as Vice President of Bioproduct Research and Development, leading an organization of 300+ scientists and support personnel who are responsible for the process and product development of the diverse Lilly large molecule portfolio. He has over 25 years of experience in the pharma/biotech industry and includes experience in both the small molecule and large molecule areas. He has been involved in the development and commercialization of over 20 branded products during this time.
Prior to joining Lilly, Arup spent 10 years with Glaxo Wellcome Inc/GlaxoSmithKline in Research Triangle Park, North Carolina.
Arup holds a B.S. in Chemistry and a Ph.D. in Pharmaceutics from the University of Iowa.
William Rust, Ph.D., Director
Dr. Rust is both an active member of the Board of Directors and a shareholder in the company. He has successfully raised several rounds of private equity funding to support Seraxis growing operations. Dr. Rust works with other members of the Board to design a long-term corporate strategy that delivers maximum value to shareholders while keeping on target the SERAXIS mission of curing type 1 diabetes.
Bernie Treidl, M.B.A., Director
Bernie Treidl has spent more than 30 years in the biotechnology industry starting, operating and guiding biotech companies. Prior to being a Seraxis director, Bernie was co-founder, President and CEO of ChemGen Corp. a biotech company that developed a fermentation process to make a key AIDS drug intermediate and later focused on the development and manufacture of enzymes used to improve the efficiency of meat-animal production. Bernie holds a B.A.Sc. and M.Eng. in Electrical Engineering from the University of Toronto and an MBA from Harvard Business School.
James N. Topper, M.D., Ph.D.
Jamie is a Managing Partner of Frazier Healthcare Partners’ Life Sciences team. Throughout his 16 years as a Managing Partner, he has invested across over 35 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. He has led many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). In addition to Seraxis, Jamie currently represents Frazier on the boards of Allena Pharmaceuticals (NASDAQ: ALNA), Alpine Immune Sciences (NASDAQ: ALPN), Amunix Pharmaceuticals, AnaptysBio (NASDAQ: ANAB), Lassen Therapeutics, and PhathomPharmaceuticals (NASDAQ: PHAT). He is also a board observer for Alcresta Therapeutics and Sojournix. Jamie received his M.D. and Ph.D. in Biophysics from Stanford and holds a B.S. from the University of Michigan.
Gi-Hyeok Yang, Ph.D., Director
Gi-Hyeok Yang is Vice President, MedyTox Inc. Prior to this role, he served as senior managing director and executive director of MedyTox Inc. In addition to being on Seraxis Board, Gi-Hyeok also serves as a member of the Board of MedyTox Inc. He completed post-doctoral fellowships at both Michigan State University and the Korea Research Institute of Bioscience and Biotechnology. Gi-Hyeok holds a Ph.D. from the Korea Advanced Institute of Science and Technology (KAIST).
Marie Csete, M.D., Ph.D.
Professor of Anesthesiology, USC Keck School of Medicine. Visiting Associate, Caltech Medical Engineering. Director Transplant Anesthesiology (former): UCSF, UCLA, Emory. Founding Director (former), Emory-Georgia Tech Human Embryonic Stem Cell Core. Former CSO, California Institute for Regenerative Medicine. CSO, Huntington Medical Research Institutes (former).
Giuseppe Orlando, M.D., Ph.D.
Assistant Professor, Wake Forest School of Medicine. Transplant surgeon scientist, specializing in kidney and pancreas transplantation, and organ bioengineering, regeneration and repair.
Carani Sanjeevi, M.D., Ph.D.
Professor, Karolinska Institute Division of Rheumatology, Karolinska University Hospital. Head of Molecular Immunogenetics Group, Center of Molecular Medicine, Karolinska University Hospital, Stockholm.
Seraxis is interested in pursuing strategic partnerships with organizations interested in bringing novel therapies to patients. Seraxis invites proposals of scientific collaborations and licensing opportunities around either of its technologies, across geographies and indications.
Interested parties may contact our Business Development Team.